GLOW2 – Zenkuda demonstrated robust ≥2 -step improvement in Diabetic Retinopathy Severity Score (DRSS) at the 6-month dosing interval GLOW2: Zenkuda (n=130). Week 44 and Week 48 (LOCF) represents the last available observation while on randomized treatment, within the Week 44 and Week 48 visit windows, respectively. Weighted percentages are based on weighted average of observed estimates across strata using CMH weights. 59.3% 62.5% 0% 25% 50% 75% Week 44 Week 48 Proportion of patients with ≥2 -Step improvement in DRSS from Baseline to Week 44 and Week 48 GLOW2 Weeks 0 4 8 12 16 20 24 28 32 36 40 44 48 Zenkuda 3 -month interval 6 -month interval Primary Endpoint 6 months after prior Zenkuda dose 1 month after last Zenkuda dose GLOW2 dosing schedule Primary Endpoint 10